Pfizer, Merck, and Astellas Announce Positive Phase 3 Results for Bladder Cancer Therapy

Key Facts

1The combination of PADCEV and Keytruda showed a 47% reduction in the risk of recurrence or death in patients with muscle-invasive bladder cancer.

2The clinical trial (EV-304/KEYNOTE-B15) resulted in a 35% reduction in the risk of death compared to standard chemotherapy.

3The results target patients eligible for cisplatin-based chemotherapy both before and after surgery.

Pfizer, Merck, and Astellas Pharma have announced successful Phase 3 trial results for their combination therapy targeting muscle-invasive bladder cancer. The clinical trial, known as EV-304/KEYNOTE-B15, demonstrated that the combination of PADCEV and Keytruda significantly improves survival outcomes. Data showed a 47% reduction in the risk of disease recurrence or death compared to standard chemotherapy. Furthermore, the treatment resulted in a 35% reduction in the overall risk of death for patients eligible for cisplatin-based therapy both before and after surgery. These strong results strengthen the market position of all three pharmaceutical giants in the high-growth oncology sector. The successful trial is expected to expand the indications for these high-revenue drugs, potentially boosting future revenue streams.